Endotracheal Tube PlacementNCT06939998
A Nontraditional Approach for Awake Fiberoptic Nasotracheal Intubation.
A study testing FOBIET and CFOBI in people with Endotracheal Tube Placement, run by Alexandria University at 1 site in Egypt.
Trial summary
The goal of this clinical trial is to learn if awake nasotracheal fiberoptic intubation through an endotracheal tube inserted in the nasopharynx would be quick and have fewer complications than the conventional technique. Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Endotracheal Tube Placement
- What is being tested?
- FOBIET and CFOBI
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 112 participants
- Where
- 1 siteEgypt
- Study dates
- 15 May 2025to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- age between 20 and 60 years,
- ASA (American Society of Anesthesiologists) grade I to IV, and an
- indication of awake fiberoptic nasal intubation.
Who cannot join
- Patients who refuse to undergo the procedure and
- patients with any absolute contraindication for nasal intubation like head trauma, suspected base of skull fractures, nasal mass, or deviated nasal septum
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Nontraditional Approach for Awake Fiberoptic Nasotracheal Intubation. A Randomized Controlled Superiority Trial
The goal of this clinical trial is to learn if awake nasotracheal fiberoptic intubation through an endotracheal tube inserted in the nasopharynx would be quick and have fewer complications than the conventional technique. The main questions it aims to answer are:
which technique of intubation is faster, with more patient comfort and satisfaction? which technique has fewer complications like cough, bleeding, and laryngospasm? Researchers will compare intubation with the conventional fiberoptic technique for intubation to awake nasotracheal fiberoptic intubation through an endotracheal tube inserted in the nasopharynx.
Read more
Participants will be monitored throughout the procedure for:
- The duration of the intubation procedure
- The mean peripheral oxygen saturation
- Hemodynamic variables (HR, MAP)
Read the detailed description
A nontraditional approach for awake fiberoptic nasotracheal intubation. A randomized controlled superiority trial Introduction It takes skill and specialized equipment to intubate someone with an anticipated difficult airway. The American Society of Anaesthesiologists and other European authors advise awake fiberoptic intubation (FOB). An awake patient can protect the airway. When a patient breathes independently until the airway is secured, awake fiberoptic intubation increases safety. In addition to requiring awake flexible fiberoptic intubation, difficult airway instances such as limited jaw mobility, restricted mouth opening, surgical interventions, or procedures planned in the oral cavity also require the nasotracheal route for intubation. Compared to oral intubation, nasal intubation is typically more straightforward and more successful.
Negotiating the endotracheal tube can be challenging since initial resistance is experienced during the passage of the bronchoscope and endotracheal tube (ET). However, the nasal approach gives an aligned airway to the larynx and trachea and holds the tube more stably. Gentle force is needed to overcome this resistance, which could cause the nose passage's friable mucosa to bleed. Coughing during a flexible fiberoptic bronchoscopy can make it difficult to see the vocal cord because bleeding in the nasopharynx and oropharynx can irritate the airway and cause coughing.
Berman and Ovassapian airways are available to help with awake flexible fiberoptic intubation via oral route. These airways provide a passageway for the ET tube and bronchoscope. However, the nasal approach does not have access to such an airway. A fiberoptic bronchoscope is usually passed through the more patent nostril to reach the nasopharynx. It then follows the main nasal pathway at the nose floor along the superior aspect of the hard palate and the lateral aspect of the nasal septum inferior to the lower turbinate. Once there, the operator can identify the pharyngeal structures, such as the base of the tongue and the epiglottis, which are primarily "in-fall" and prevent clear views of the larynx, necessitating a jaw thrust to visualize the laryngeal structures for patients who are scheduled to be intubated under general anesthesia so a wake fiberoptic is preferred in anticipating difficult airway.
An endotracheal tube (ET) can be inserted along the FOB cable that has already advanced into the trachea, making FOB nasal intubation easier and faster. This is achieved by inserting a modified split tube nasally down to or near the larynx, which allows the FOB cable to be immediately in front of the larynx without the need to confirm the anatomical details of the nasopharyngeal-laryngeal journey required during classic nasal FOB intubation.
This study hypothesized that awake nasotracheal fiberoptic intubation through an endotracheal tube inserted in the nasopharynx would be quick and have fewer complications than the conventional technique. This study compares the time to intubation and safety of FOB nasal intubation as classically done and thorough endotracheal tube.
Objectives The study's primary objective will be to determine the time taken for intubation. Its secondary objectives will be to observe desaturation episodes during the procedure, complications like cough, bleeding, and laryngospasm, and patient comfort and satisfaction.
A single-blind, randomized control superiority trial will be conducted after approval from the institutional ethical committee, and the trial will be registered with the clinical trial registry. The trial will be conducted at Alexandra University Hospital. The selection of patients will be based on inclusion criteria. The study will comply with the principles outlined in the Declaration of Helsinki. After explaining the nature and purpose of the trial, informed consent will be obtained from all participants. Before enrolling the patients, the procedure will be described, and informed consent will be taken for nasotracheal fiberoptic intubation, emergency surgical tracheostomy, delayed extubation, anesthesia, and surgery will be taken from patients.
After assessing the inclusion criteria, 112 patients will be randomized using a computer-generated randomization sequence. These selected patients will be divided into two groups. Group allocation (1:1 allocation ratio) will be done using a sealed envelope technique, and patients will be allocated equally to either group CFOBI (conventional fiberoptic intubation) or group FOBIET (fiberoptic intubation through an endotracheal tube). In the traditional fiberoptic intubation group (N = 56), a flexible fiberoptic bronchoscope is first introduced through the nasal passage. In the study group, an endotracheal tube is introduced in the nasal cavity first, and then a flexible fiberoptic bronchoscope will be introduced.
Interventions:
All patients will be premeditated with midazolam 0.03 mg/kg just before the surgery. Five ml of 2% lignocaine + 1 ml adrenaline will be nebulized over twenty minutes to provide a topical anesthetic. One drop of xylometazoline 0.1% will be administered to each patient's nostrils. Before the treatment, a 10% lignocaine spray would be applied bilaterally in the facial pillars. Both groups' tongue depressors will measure how well the topical anesthetic works. A dose of 0.03 to 0.05 mg/kg of injectable midazolam would be administered, and sedation (with a targeted Ramsay sedation score of 3) will be initiated with an intravenous (IV) injection of 1 microgram per kilogram of loading dexmedetomidine over 10 minutes. More patent nostrils will be selected for the treatment, and nasal patency will be performed.
-In the CFOBI group: a 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected.
-In the FOBIET group: an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigators can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen.
After identifying the vocal cords, 2 ml of 2% lidocaine will be sprayed over the supraglottic area using the bronchoscope's working channel. An additional 2 ml of 2% lidocaine will then be sprayed directly onto the vocal cords, after which the tip of an endotracheal (ET) tube will be carefully inserted into them.
Bilateral equal air entry and capnography will verify that the ET tube is correctly positioned in the trachea in both groups after the tube has been successfully passed through the vocal cords and the carina has been identified. The tube will then be secured, and the cuff will inflate.
Measurements:
- The duration of the intubation procedure will be recorded in minutes, starting from the point at which the scope is inserted into the nares and ending with the ET cuff being inflated.
- The mean peripheral oxygen saturation (Spo2) will be recorded throughout the process.
- Hemodynamic variables (HR, MAP) will be recorded at three different time intervals (baseline, at the beginning of the procedure during insertion of the endotracheal tube through the nostril in one group, during fiberscope insertion in the other group, and at the end of the study after confirmation of the endotracheal tube in place).
- Intubation condition scores will be assessed by vocal cord movement (1 = open, 2 = moving, 3 = closing, 4 = closed), coughing (1 = none, 2 = one gag or cough only, 3 = >1 gag or cough, but acceptable conditions, 4 = unacceptable conditions).
- intubation comfort score (1=noreaction,2=griming,3=verberal objection,4=defensive movement of hands and head).
- The airway obstruction score of Downes and Raphaelly. Upper airway respiratory distress is graded as: Absent= (0), Mild=(1-3),Moderate=(4-6),Severe=(≥7).
- Laryngospasm and bleeding incidence will be noted.
Data Collection:
Data will be collected by trained research personnel, entered into a secure database, and maintained following Good Clinical Practice (GCP) guidelines.
Data Analysis: Statistical analysis will be performed using appropriate tests to compare primary and secondary endpoints.
Sample Size:
The sample size was determined for the primary outcome (time for intubation), aiming to demonstrate the new approach's superiority over the conventional approach. A 30 % reduction in time for intubation (min) between groups was considered clinically relevant. Based on another trial , the investigators assumed a time for intubation of 6.15 ± 3.0 min (in patients who underwent conventional awake fiberoptic intubation). Assuming α=0.05 and power=0.90 for a 30 % difference in time for intubation using a two-sided Χ2 test, the calculated sample size will be 112. The sample size required per group will be 56.
- Conditions
- Endotracheal Tube Placement
- Being tested
- FOBIET, CFOBI
- Keywords
- nasotracheal fiberoptic intubation through ETT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FOBIETProcedure or surgery
Also called fiberoptic intubation through nasal endotracheal tube
an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigator can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen.
After identifying the vocal cords, 2 ml of 2% lidocaine will be sprayed over the supraglottic area using the bronchoscope's working channel. An additional 2 ml of 2% lidocaine will then be sprayed directly onto the vocal cords, after which the tip of an endotracheal (ET) tube will be carefully inserted into them.
CFOBIProcedure or surgery
a 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected.
| Study group | Role | What they receive |
|---|---|---|
| CFOBI conventional fiberoptic intubation | Experimental | a 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected. Receives: Procedure: CFOBI |
| FOBIET nasotracheal fiberoptic intubation through an endotracheal tube in the nasopharynx | Active comparator | FOBIET: an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigator can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen Receives: Procedure: FOBIET |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time taken for intubation.
The duration of the intubation procedure will be recorded in minutes, starting from the point at which the scope is inserted into the nares and ending with the ET cuff being inflated.
Measured: up to 7 month
Secondary outcomes (4)
Number of desaturation episodes
The mean peripheral oxygen saturation (Spo2) will be recorded throughout the process and SpO2 below 90% will be considered as a desaturation episode.
Measured: up to 7 month
Occurrence of airway obstruction.
The airway obstruction score of Downes and Raphaelly, will be recorded during the intervention. Upper airway respiratory distress is graded as: Absent= (0), Mild=(1-3),Moderate=(4-6),Severe=(≥7).
Measured: up to 7 month
Patient comfort
intubation comfort score will be recorded during the procedure(1=noreaction,2=griming,3=verbal objection,4=defensive movement of hands and head)
Measured: up to 7 month
Occurrence of other adverse effects
any other complication during intervention will be recorded
Measured: up to 7 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2025
- Study start15 May 2025 (estimated)
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endotracheal Tube PlacementStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 112 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Islam Elbardan, Dr, Principal investigator, University of Alexandria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06939998
- Sponsor's protocol ID
- IRP number 00012098
- Status last verified
- Jan 2025
- First submitted
- 4 Mar 2025
- Last updated
- 23 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Nontraditional Approach for Awake Fiberoptic Nasotracheal Intubation. A Randomized Controlled Superiority Trial
- ClinicalTrials.gov ID
- NCT06939998
- Acronym / sponsor ID
- IRP number 00012098
- Conditions
- Endotracheal Tube Placement
- Keywords
- nasotracheal fiberoptic intubation through ETT
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 112 participants (estimated)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 15 May 2025 (estimated)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 23 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if awake nasotracheal fiberoptic intubation through an endotracheal tube inserted in the nasopharynx would be quick and have fewer complications than the conventional technique. The main questions it aims to answer are:
which technique of intubation is faster, with more patient comfort and satisfaction? which technique has fewer complications like cough, bleeding, and laryngospasm? Researchers will compare intubation with the conventional fiberoptic technique for intubation to awake nasotracheal fiberoptic intubation through an endotracheal tube inserted in the nasopharynx.
Participants will be monitored throughout the procedure for:
- The duration of the intubation procedure
- The mean peripheral oxygen saturation
- Hemodynamic variables (HR, MAP)
Detailed description
A nontraditional approach for awake fiberoptic nasotracheal intubation. A randomized controlled superiority trial Introduction It takes skill and specialized equipment to intubate someone with an anticipated difficult airway. The American Society of Anaesthesiologists and other European authors advise awake fiberoptic intubation (FOB). An awake patient can protect the airway. When a patient breathes independently until the airway is secured, awake fiberoptic intubation increases safety. In addition to requiring awake flexible fiberoptic intubation, difficult airway instances such as limited jaw mobility, restricted mouth opening, surgical interventions, or procedures planned in the oral cavity also require the nasotracheal route for intubation. Compared to oral intubation, nasal intubation is typically more straightforward and more successful.
Negotiating the endotracheal tube can be challenging since initial resistance is experienced during the passage of the bronchoscope and endotracheal tube (ET). However, the nasal approach gives an aligned airway to the larynx and trachea and holds the tube more stably. Gentle force is needed to overcome this resistance, which could cause the nose passage's friable mucosa to bleed. Coughing during a flexible fiberoptic bronchoscopy can make it difficult to see the vocal cord because bleeding in the nasopharynx and oropharynx can irritate the airway and cause coughing.
Berman and Ovassapian airways are available to help with awake flexible fiberoptic intubation via oral route. These airways provide a passageway for the ET tube and bronchoscope. However, the nasal approach does not have access to such an airway. A fiberoptic bronchoscope is usually passed through the more patent nostril to reach the nasopharynx. It then follows the main nasal pathway at the nose floor along the superior aspect of the hard palate and the lateral aspect of the nasal septum inferior to the lower turbinate. Once there, the operator can identify the pharyngeal structures, such as the base of the tongue and the epiglottis, which are primarily "in-fall" and prevent clear views of the larynx, necessitating a jaw thrust to visualize the laryngeal structures for patients who are scheduled to be intubated under general anesthesia so a wake fiberoptic is preferred in anticipating difficult airway.
An endotracheal tube (ET) can be inserted along the FOB cable that has already advanced into the trachea, making FOB nasal intubation easier and faster. This is achieved by inserting a modified split tube nasally down to or near the larynx, which allows the FOB cable to be immediately in front of the larynx without the need to confirm the anatomical details of the nasopharyngeal-laryngeal journey required during classic nasal FOB intubation.
This study hypothesized that awake nasotracheal fiberoptic intubation through an endotracheal tube inserted in the nasopharynx would be quick and have fewer complications than the conventional technique. This study compares the time to intubation and safety of FOB nasal intubation as classically done and thorough endotracheal tube.
Objectives The study's primary objective will be to determine the time taken for intubation. Its secondary objectives will be to observe desaturation episodes during the procedure, complications like cough, bleeding, and laryngospasm, and patient comfort and satisfaction.
A single-blind, randomized control superiority trial will be conducted after approval from the institutional ethical committee, and the trial will be registered with the clinical trial registry. The trial will be conducted at Alexandra University Hospital. The selection of patients will be based on inclusion criteria. The study will comply with the principles outlined in the Declaration of Helsinki. After explaining the nature and purpose of the trial, informed consent will be obtained from all participants. Before enrolling the patients, the procedure will be described, and informed consent will be taken for nasotracheal fiberoptic intubation, emergency surgical tracheostomy, delayed extubation, anesthesia, and surgery will be taken from patients.
After assessing the inclusion criteria, 112 patients will be randomized using a computer-generated randomization sequence. These selected patients will be divided into two groups. Group allocation (1:1 allocation ratio) will be done using a sealed envelope technique, and patients will be allocated equally to either group CFOBI (conventional fiberoptic intubation) or group FOBIET (fiberoptic intubation through an endotracheal tube). In the traditional fiberoptic intubation group (N = 56), a flexible fiberoptic bronchoscope is first introduced through the nasal passage. In the study group, an endotracheal tube is introduced in the nasal cavity first, and then a flexible fiberoptic bronchoscope will be introduced.
Interventions:
All patients will be premeditated with midazolam 0.03 mg/kg just before the surgery. Five ml of 2% lignocaine + 1 ml adrenaline will be nebulized over twenty minutes to provide a topical anesthetic. One drop of xylometazoline 0.1% will be administered to each patient's nostrils. Before the treatment, a 10% lignocaine spray would be applied bilaterally in the facial pillars. Both groups' tongue depressors will measure how well the topical anesthetic works. A dose of 0.03 to 0.05 mg/kg of injectable midazolam would be administered, and sedation (with a targeted Ramsay sedation score of 3) will be initiated with an intravenous (IV) injection of 1 microgram per kilogram of loading dexmedetomidine over 10 minutes. More patent nostrils will be selected for the treatment, and nasal patency will be performed.
-In the CFOBI group: a 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected.
-In the FOBIET group: an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigators can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen.
After identifying the vocal cords, 2 ml of 2% lidocaine will be sprayed over the supraglottic area using the bronchoscope's working channel. An additional 2 ml of 2% lidocaine will then be sprayed directly onto the vocal cords, after which the tip of an endotracheal (ET) tube will be carefully inserted into them.
Bilateral equal air entry and capnography will verify that the ET tube is correctly positioned in the trachea in both groups after the tube has been successfully passed through the vocal cords and the carina has been identified. The tube will then be secured, and the cuff will inflate.
Measurements:
- The duration of the intubation procedure will be recorded in minutes, starting from the point at which the scope is inserted into the nares and ending with the ET cuff being inflated.
- The mean peripheral oxygen saturation (Spo2) will be recorded throughout the process.
- Hemodynamic variables (HR, MAP) will be recorded at three different time intervals (baseline, at the beginning of the procedure during insertion of the endotracheal tube through the nostril in one group, during fiberscope insertion in the other group, and at the end of the study after confirmation of the endotracheal tube in place).
- Intubation condition scores will be assessed by vocal cord movement (1 = open, 2 = moving, 3 = closing, 4 = closed), coughing (1 = none, 2 = one gag or cough only, 3 = >1 gag or cough, but acceptable conditions, 4 = unacceptable conditions).
- intubation comfort score (1=noreaction,2=griming,3=verberal objection,4=defensive movement of hands and head).
- The airway obstruction score of Downes and Raphaelly. Upper airway respiratory distress is graded as: Absent= (0), Mild=(1-3),Moderate=(4-6),Severe=(≥7).
- Laryngospasm and bleeding incidence will be noted.
Data Collection:
Data will be collected by trained research personnel, entered into a secure database, and maintained following Good Clinical Practice (GCP) guidelines.
Data Analysis: Statistical analysis will be performed using appropriate tests to compare primary and secondary endpoints.
Sample Size:
The sample size was determined for the primary outcome (time for intubation), aiming to demonstrate the new approach's superiority over the conventional approach. A 30 % reduction in time for intubation (min) between groups was considered clinically relevant. Based on another trial , the investigators assumed a time for intubation of 6.15 ± 3.0 min (in patients who underwent conventional awake fiberoptic intubation). Assuming α=0.05 and power=0.90 for a 30 % difference in time for intubation using a two-sided Χ2 test, the calculated sample size will be 112. The sample size required per group will be 56.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CFOBI conventional fiberoptic intubation | Experimental | Procedure: CFOBIa 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected. |
| FOBIET nasotracheal fiberoptic intubation through an endotracheal tube in the nasopharynx | Active comparator | Procedure: FOBIETFOBIET: an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigator can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- age between 20 and 60 years,
- ASA (American Society of Anesthesiologists) grade I to IV, and an
- indication of awake fiberoptic nasal intubation.
Key exclusion criteria (2 listed)
- Patients who refuse to undergo the procedure and
- patients with any absolute contraindication for nasal intubation like head trauma, suspected base of skull fractures, nasal mass, or deviated nasal septum
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FOBIETAlso: fiberoptic intubation through nasal endotracheal tubean endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigator can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen. After identifying the vocal cords, 2 ml of 2% lidocaine will be sprayed over the supraglottic area using the bronchoscope's working channel. An additional 2 ml of 2% lidocaine will then be sprayed directly onto the vocal cords, after which the tip of an endotracheal (ET) tube will be carefully inserted into them. | Procedure or surgery | FOBIET nasotracheal fiberoptic intubation through an endotracheal tube in the nasopharynx |
| CFOBIa 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected. | Procedure or surgery | CFOBI conventional fiberoptic intubation |
Primary outcome
Time taken for intubation.
Time frame: up to 7 month
The duration of the intubation procedure will be recorded in minutes, starting from the point at which the scope is inserted into the nares and ending with the ET cuff being inflated.
4 secondary outcomes
Number of desaturation episodes
Time frame: up to 7 month
Occurrence of airway obstruction.
Time frame: up to 7 month
Patient comfort
Time frame: up to 7 month
Occurrence of other adverse effects
Time frame: up to 7 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2025.
Related trials for Endotracheal Tube Placement
Recruiting
Comparison of Age-Based Formula and Ultrasound-Guided Subglottic Diameter Measurement for Endotracheal Tube Sizing
Endotracheal Tube Wrongly Placed During Anesthetic Procedure
Recruiting
Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion
Anesthesia, Endotracheal
Not yet recruiting
Diagnostic Accuracy of Core Stethoscope Auscultation vs. Point of Care Ultrasound in Placement of Endotracheal Tube
Intubation Complication
Not yet recruiting
Videolaryngoscopy vs Direct Laryngoscopy for Double Lumen Tube Lumen Tube Placement - A Multicentre Randomized-controlled Trial (VOLCANO Study)
One Lung Ventilation, Intubation Complication
Recruiting
Role of Point of Care Ultrasound in Endotracheal Tube Placement
Endotracheal Tube Wrongly Placed During Anesthetic Procedure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Islam Elbardan, Dr principal investigator
University of Alexandria
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FOBIET and CFOBI in people with Endotracheal Tube Placement, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hesham Elgoweini, Professor Dr (00201287740750, ethics.comm@alexmed.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time taken for intubation. (time frame: up to 7 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2025.